Not everyone is singing the praises, just a couple of longs who desperately need a reality check and would consider a drop to 25 cents a share a �buying opportunity.� The rest of us are cautiously optimistic that the trials will work out and we can recover and maybe even make some money. The company has some really fantastic drugs in testing that could revolutionize cancer treatments, if they work that is.
Like with all investments high risk high reward but sometimes people forget about the high-risk part. In this case, keep one eye on the prize and the other on the burn rate. They may just run out of gas on the last lap leaving us all hanging.
i had a long talk with dick anderson of nerx and bottom line was that he could not give me any ide a about str and fda review status and that i believe nerx has to get the domistry study done in advance of str app for ph3 which means more of a delay then most of us think. that may be one reason why the stock is going down